CN Patent

CN120731085A — 一种glp-1化合物的医药用途

Assigned to Gan and Lee Pharmaceuticals Co Ltd · Expires 2025-09-30 · 1y expired

What this patent protects

提供一种GLP‑1化合物的治疗或预防痴呆和/或神经退行性疾病，尤其是阿尔茨海默症和/或帕金森病的方法及其相应的制药用途。与阳性对照药司美格鲁肽、多奈哌齐、雷沙吉兰和左旋多巴胺相比，表现出了更好的改善效果。

USPTO Abstract

提供一种GLP‑1化合物的治疗或预防痴呆和/或神经退行性疾病，尤其是阿尔茨海默症和/或帕金森病的方法及其相应的制药用途。与阳性对照药司美格鲁肽、多奈哌齐、雷沙吉兰和左旋多巴胺相比，表现出了更好的改善效果。

Drugs covered by this patent

Patent Metadata

Patent number
CN120731085A
Jurisdiction
CN
Classification
—
Expires
2025-09-30
Drug substance claim
No
Drug product claim
No
Assignee
Gan and Lee Pharmaceuticals Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.